Things are looking up –

Mar. 16, 2019 – Hence the interest in a recent announcement by the Food and Drug Administration (FDA) in America that it had approved a new drug for patients with “treatment-resistant” depression, defined as having not responded adequately to at least two previous antidepressants. Of particular note is that it is based on ketamine, a recreational drug. Esketamine, as the chemical is known, is branded as Spravato by its developer, Janssen Pharmaceuticals, a branch of Johnson & Johnson.

Full Story @


Subscribe Today! Your best source of current news, information and opinion about the issues that matter to you most. Serving the treatment industry, recovery community and health and wellness professionals.